Oxaliplatin Ebewe (Oxaliplatin)

Oxaliplatin Ebewe is an alkylating agent used in the management of malignancies that respond to platinum‑based chemotherapy.

• Colorectal cancer: Enhances survival by inhibiting tumor cell replication.
• Gastric cancer: Contributes to tumor shrinkage when combined with other agents.
• Pancreatic cancer: Used in combination regimens to improve response rates.

• Oxaliplatin exerts its antitumor activity by forming reactive platinum complexes that covalently bind to DNA bases, creating intra‑ and interstrand cross‑links. These cross‑links disrupt DNA replication and transcription, ultimately triggering apoptosis in rapidly dividing cancer cells.

Oxaliplatin Ebewe may cause a range of adverse reactions during therapy.

Common Side Effects

• Peripheral neuropathy: Tingling or numbness, often in the hands and feet.
• Nausea and vomiting: May occur during or after infusion.
• Diarrhea: Loose stools that can range from mild to moderate.
• Fatigue: Generalized tiredness not relieved by rest.
• Thrombocytopenia: Reduced platelet count, increasing bleeding risk.

Serious or Rare Side Effects

• Severe neuropathy: Persistent sensory loss that may be irreversible.
• Anaphylactic reactions: Rapid onset of breathing difficulty, rash, or hypotension.
• Hematologic toxicity: Significant drops in white blood cells or red blood cells.
• Hepatotoxicity: Elevated liver enzymes indicating liver stress.
• Acute pulmonary toxicity: Shortness of breath or lung infiltrates.

When using Oxaliplatin Ebewe, clinicians should observe several safety measures.

• Renal function monitoring: Assess baseline and periodic kidney function tests.
• Neuropathy assessment: Conduct regular neurological examinations.
• Hematologic monitoring: Perform CBC checks regularly.
• Premedication: Consider anti‑emetic prophylaxis before infusion.
• Drug compatibility: Verify that infusion solutions are compatible.

Store at 2-8°C: Keep refrigerated, protect from light, do not freeze.

Oxaliplatin Ebewe can interact with several concomitant medications.

Major Interactions (Avoid)

• Nephrotoxic agents: Concurrent use may worsen kidney injury.
• High‑dose vitamin C: May reduce platinum‑based drug efficacy.

Moderate Interactions (Monitor Closely)

• Anticoagulants anticoants: Increased bleeding risk.
• CYP enzyme‑inducing drugs: May alter drug clearance.
• NSAIDs: Potential for additive nephrotoxicity.
• Proton pump inhibitors: May affect gastric pH and drug stability.
• Herbal supplements such as ginseng: May influence metabolic pathways.